Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. (Q46877112)

26 December 2017

title

Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. (English)

1 reference

26 December 2017

1 reference

Yu-Qiang Mi

1

1 reference

26 December 2017

Qi-Yu Shi

2

1 reference

26 December 2017

Liang Xu

3

1 reference

26 December 2017

Rui-Fang Shi

4

1 reference

26 December 2017

Yong-Gang Liu

5

1 reference

26 December 2017

Ping Li

6

1 reference

26 December 2017

Feng Shen

7

1 reference

26 December 2017

Wei Lu

8

1 reference

26 December 2017

Jian-Gao Fan

9

1 reference

26 December 2017

publication date

7 September 2014

1 reference

26 December 2017

Digestive Diseases and Sciences

published in

1 reference

26 December 2017

volume

60

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

243-251

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s10620-014-3341-x

exact match

0 references

cites work

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Chronic hepatitis B in Asia-new insights from the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Viral and host causes of fatty liver in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Noninvasive liver steatosis quantification using MRI techniques combined with blood markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Shear elasticity probe for soft tissues with 1-D transient elastography.

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

21 January 2018

12 December 2020

Transient elastography: Kill two birds with one stone?

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Global epidemiology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Liver stiffness measurement: simplicity is prerequisite for reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3341-X

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

12 December 2020

Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C

1 reference

12 December 2020

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

1 reference

12 December 2020

Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis

1 reference

12 December 2020

Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity

1 reference

12 December 2020

Hepatic steatosis: a common reason for elevated alanine aminotransferase levels in HBsAg-positive chronic hepatitis B patients with low HBV DNA loads

1 reference

12 December 2020

Determination of reliability criteria for liver stiffness evaluation by transient elastography

1 reference

12 December 2020

Impact of non-alcoholic fatty liver disease on chronic hepatitis B

1 reference

12 December 2020

Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver

1 reference

12 December 2020

Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography

1 reference

12 December 2020

Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases

1 reference

12 December 2020

Quantification of liver fat using magnetic resonance spectroscopy

1 reference

12 December 2020

Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis

1 reference

12 December 2020

10.1007/S10620-014-3341-X

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

25194851

1 reference

26 December 2017